Wei Zhang, Mark J. Ratain, M. Eileen Dolan
The exploration of quantitative variation in complex traits such as gene expression and drug response in human populations has become one of the major priorities for medical genetics. The...
Wei Zhang, Mark J. Ratain, M. Eileen Dolan
The exploration of quantitative variation in complex traits such as gene expression and drug response in human populations has become one of the major priorities for medical genetics. The...
Karrison, Theodore G., Maitland, Michael L., Stadler, Walter M., Ratain, Mark J.
Background The primary objective of phase II cancer clinical trials is to determine whether a new regimen has sufficient activity to warrant further study, with activity generally defined as tumor...
Global gene expression as a function of germline genetic variation (2005)
French, Deborah, Wilkinson, Mark R., Yang, Wenjian, De Chaisemartin, Luc, Cook, Edwin H., Das, Soma, ...
Common, functional, germline genetic polymorphisms have been associated with clinical cancer outcomes. Little attention has been paid to the potential phenotypic consequences of germline genetic...
Global Gene Expression as a Function of Germline Genetic Variation (2005)
French, Deborah, Wilkinson, Mark R., Yang, Wenjian, De Chaisemartin, Luc, Cook, Edwin H., Das, Soma, ...
Common, functional, germline genetic polymorphisms have been associated with clinical cancer outcomes. There has been little attention to the potential phenotypic consequences of germline genetic...
Helft, Paul R., Ratain, Mark J., Epstein, Richard A., Siegler, Mark
In recent years, several research subjects have told us that they had bought or intended to buy stock in the companies sponsoring the clinical trials in which they were enrolled. This situation has...
Mick, Rosemarie, Lane, Neil, Daugherty, Christopher, Ratain, Mark J.
Background: The conventional phase I trial design yields an estimate of the maximum tolerated dose (MTD) of a new drug defined from treatment toxic effects observed in a small heterogenous cohort of...
Phase I Study of Adozelesin Administered by 24-Hour Continuous Intravenous Infusion (1994)
Fleming, Gini F., Ratain, Mark J., O'Brien, Sheila M., Schilsky, Richard L., Hoffman, Philip C., Richards, Jon M., ...
Background Adozelesin, a synthetic analogue of the antitumor antibiotic CC-1065, is the first of a class of potent sequence-specific alkylating agents to be brought to clinical trial. In preclinical...
Lichtman, Stuart M., Ratain, Mark J., Van Echo, David A., Rosner, Gary, Egorin, Merrill J., Budman, Daniel R., ...
Background: Chemotherapy-induced myelosuppression often limits escalation of cancer chemotherapy doses. Cyclophosphamide, an alkylating agent, is an ideal candidate for dose escalation: A log-linear...
Mick, Rosemarie, Ratain, Mark J.
Background: A widely used phase I design in clinical trials of chemotherapy for cancer and for AIDS (acquired immunodeficiency syndrome) allows for dose escalation in cohorts of three to six...
Phase III Trial of Erythropoietin in the Treatment of Cisplatin-Associated Anemia (1992)
Miller, Carole B., Platanias, Leonidas C., Mills, Sharon R., Zahurak, Marianna L., Ratain, Mark J., Ettinger, David S., ...
Background: Cancer Patients undergoing Chemotherapy with cisplatin-containing regimens often develop anemia. Al-though the cause is multifactorial, erythropoietin deficiency appears to play an...
Modeling Interpatient Pharmacodynamic Variability of Etoposide (1991)
Mick, Rosemarie, Ratain, Mark J.
This report describes approaches to modeling interpatient pharmacodynamic variability of etoposide effect as measured by white blood cell count nadir. Such models may be utilized in adaptive control...
Schilsky, Richard L., Ratain, Mark J.
The clinical formulation of leucovorin calcium (leucovorin, LV) is a mixture of stereoisomers [(6R,S)-5-formyltetrahydrofolate], which have been shown to differ significantly in plasma clearance and...
Low-Dose Interferon Alfa-2b in the Treatment of Hairy Cell Leukemia (1989)
Moormeier, Jill A., Ratain, Mark J., Westbrook, Carol A., Vardiman, James W., Daly, Karen M., Golomb, Harvey M.
Twenty-two patients with hairy cell leukemia were treated with low-dose interferon alfa-2b (0.2 × 106 U/m2 given three times weekly) for 6–12 months. The overall response rate was 54%,...
Hydroxyurea and Etoposide: In Vitro Synergy and Phase I Clinical Trial (1988)
Ratain, Mark J., Schilsky, Richard L., Wojack, Bette R., Simon, Todd, Senekjian, Elizabeth K., Vogelzang, Nicholas J.
L1210 murine leukemia cells were treated with hydroxyurea (10–200 μM) for 24 hours and/or etoposide (0.17–3.4 μM) for 2 hours. Combination treatments used a fixed molar hydroxyurea:...
Parsad, Sandeep D, Ratain, Mark J
Standardised dosing can improve the safety of prescribing
Searching for Tissue-Specific Expression Pattern-Linked Nucleotides of UGT1A Isoforms
Zhang, Wei, Liu, Wanqing, Innocenti, Federico, Ratain, Mark J.
UDP-glucuronosyltransferases 1A isoforms belong to a superfamily of microsomal enzymes responsible for glucuronidation of numerous endogenous and exogenous compounds. The nine functional UGT1A...
The role of pharmacogenetics in cancer therapeutics
Yong, Wei Peng, Innocenti, Federico, Ratain, Mark J
The variability in treatment responses and narrow therapeutic index of anticancer drugs are some of the key challenges oncologists face. The knowledge of pharmacogenetics can potentially aid in the...
The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics
Zhang, Wei, Ratain, Mark J., Dolan, M. Eileen
The exploration of quantitative variation in complex traits such as gene expression and drug response in human populations has become one of the major priorities for medical genetics. The...